Free Trial
NASDAQ:ONCT

Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

Oncternal Therapeutics logo
$0.53 0.00 (0.00%)
As of 04/29/2025

About Oncternal Therapeutics Stock (NASDAQ:ONCT)

Key Stats

Today's Range
$0.53
$0.53
50-Day Range
$0.53
$0.53
52-Week Range
$0.53
$7.83
Volume
N/A
Average Volume
85,982 shs
Market Capitalization
$1.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Hold

Company Overview

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Receive ONCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONCT Stock News Headlines

How high will gold surge?
Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold … and reveals a little-known way to get ahead of this bull market.
Oncternal Therapeutics Reports Q3 2024 Earnings
See More Headlines

ONCT Stock Analysis - Frequently Asked Questions

Oncternal Therapeutics' stock was trading at $0.5266 on January 1st, 2025. Since then, ONCT shares have increased by 0.0% and is now trading at $0.5266.
View the best growth stocks for 2025 here
.

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) announced its earnings results on Thursday, August, 8th. The company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.14. The company earned $0.80 million during the quarter, compared to analyst estimates of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,599.95% and a negative trailing twelve-month return on equity of 177.58%.
Read the conference call transcript
.

Shares of Oncternal Therapeutics reverse split on the morning of Monday, January 8th 2024.The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncternal Therapeutics investors own include NIO (NIO), Walt Disney (DIS), Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

Last Earnings
8/08/2024
Today
6/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ONCT
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$18.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+1,799.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.48 million
Net Margins
-1,599.95%
Pretax Margin
-1,599.95%

Debt

Sales & Book Value

Annual Sales
$790 thousand
Price / Cash Flow
N/A
Book Value
$10.19 per share
Price / Book
0.05

Miscellaneous

Free Float
2,628,000
Market Cap
$1.56 million
Optionable
No Data
Beta
1.18
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ONCT) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners